848497-98-3

Basic information

• Product Name: CYCLOBUTYL-METHYL-AMINE HYDROCHLORIDE
• Synonyms: N-MethylcyclobutanaMine hydrochloride;Cyclobutyl-methyl-amine x HCl, 95%
• CAS NO: 848497-98-3
• Molecular Formula: C₅H₁₁N*ClH
• Molecular Weight: 0
• Mol File: 848497-98-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: CYCLOBUTYL-METHYL-AMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOBUTYL-METHYL-AMINE HYDROCHLORIDE(848497-98-3)
• EPA Substance Registry System: CYCLOBUTYL-METHYL-AMINE HYDROCHLORIDE(848497-98-3)

Safety Data

• Hazardous Substances Data: 848497-98-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CYCLOBUTYL-METHYL-AMINE HYDROCHLORIDE is used as a reagent in the synthesis of pharmaceuticals for its ability to contribute to the creation of versatile building blocks. Its high reactivity allows for the development of a wide range of medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, CYCLOBUTYL-METHYL-AMINE HYDROCHLORIDE is utilized as a precursor in the production of various agrochemicals, playing a significant role in the synthesis of compounds that contribute to crop protection and enhancement.
Used in Specialty Chemicals Production:
CYCLOBUTYL-METHYL-AMINE HYDROCHLORIDE is employed as a building block for the synthesis of specialty chemicals, where its unique properties are leveraged to produce compounds with specific applications in various industries.
Used as a Catalyst in Chemical Reactions:
Beyond its role as a building block, CYCLOBUTYL-METHYL-AMINE HYDROCHLORIDE can also function as a catalyst in certain chemical reactions, facilitating processes and enhancing the efficiency of chemical transformations.

InChI:InChI=1/C5H11N.ClH/c1-6-5-3-2-4-5;/h5-6H,2-4H2,1H3;1H

Upstream product

• 87055-64-9 N-cyclobutylformamide 
• 1180501-53-4 tert-butyl cyclobutyl(methyl)carbamate 

Downstream Products

• 848497-97-2 (2S)-N-cyclobutyl-N-methyl-2-(tert-butoxycarbonylamino)-2-cyclohexylacetamide 
• 848498-06-6 (S)-[(N-cyclobutyl-N-methylcarbamoyl)-(4-oxocyclohexyl)methyl]carbamic acid tert-butyl ester 
• 1163790-92-8 4-{(S)-4-carboxy-2-[(5-{2-[(S)-2-(cyclobutyl-methyl-carbamoyl)-pyrrolidin-1-yl]-2-oxo-ethoxy}-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 

Relevant articles and documents

Targeting carnitine biosynthesis: Discovery of new inhibitors against γ-butyrobetaine hydroxylase

γ-Butyrobetaine hydroxylase (BBOX) catalyzes the conversion of gamma butyrobetaine (GBB) to l-carnitine, which is involved in the generation of metabolic energy from long-chain fatty acids. BBOX inhibitor 3-(1,1,1-trimethylhydrazin-1-ium-2-yl)propanoate (

Selective κ-opioid agonists: Synthesis and structure-activity relationships of piperidines incorporating an oxo-containing acyl group

This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2- (aminomethyl)piperidine derivatives, using κ-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their κ-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]- 1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED50s of 0.47 and 0.73 μmol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective κ-agonists, has a reduced propensity to cause a number of κ-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED50 of 26.5 μmol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.